A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies. In mice, the substance kills degenerated cells and allows testicular tumors to shrink. Researchers at the University of Bonn were able to demonstrate this in a recent study. However, first clinical trials are still pending. The work has now been published in the “Journal of Cellular and Molecular Medicine”.
Testicular cancer is the most common malignant tumor disease in men between 20 and 40 years of age. It can usually be treated well. In some cases, however, the cancer hardly responds or does not respond at all to treatment.
A substance that was originally destined to be an innovative contraceptive is offering new hope in these cases. An experimental drug with the cryptic name JQ1 blocks sperm maturation and was discussed to be a male contraceptive. Instead, it may be suitable for cancer therapy.
JQ1 belongs to a new class of drugs with far-reaching abilities: its members fundamentally influence which genes in the cell are active and which are not. The hereditary material DNA is similar to an extremely long strip of Morse code, on which the assembly instructions for the cellular molecules are found. To fit into the cell nuclei, this strip of Morse code is wrapped around small protein balls at regular intervals – the histones. Histones and DNA together resemble a string of pearls.
However, the histones do not only play a structural role. They also feature chemical tags – called methyl or acetyl groups. These tags signal to the synthesis machinery in the cell whether the strip of Morse code should be read at this point or not. “JQ1 inhibits those proteins that read these histone marks and thus changes the gene activity in the cell,” explains Prof. Hubert Schorle from the Institute for Pathology at the University of Bonn.
The cancer cells react very sensitive to these changes: they activate a suicide program, called apoptosis. “In a testicular cancer mouse model, the tumors began to shrink after administering JQ1,” explains the lead author of the study, Sina Jostes. “In contrast, healthy skin cells seem to tolerate JQ1 very well.”
Especially effective in combination
Besides JQ1, other drugs that alter the marks of the histones are also known. One of these is romidepsin. The laboratory in Bonn was recently able to show that romidepsin is also very effective at fighting testicular cancer cells. Unlike JQ1, romidepsin is already approved for the treatment of patients with certain types of cancer.
“In our study, we treated mice with both JQ1 and romidepsin,” explains Dr. Daniel Nettersheim, who helped in planning and performing the studies. “This way, we achieved a similar effect alike JQ1 or romidepsin treatment alone, but we could reduce the quantities of both substances. Such a combination therapy to treat testicular tumors may be much better tolerated. Chemotherapy-resistant patients could also benefit from this.” However, clinical studies are now needed to move the treatment towards the clinics.
Besides scientists from the University of Bonn, the studies also involved researchers from the University of St. Gallen (Switzerland) and Harvard Medical School (USA).
Sina Jostes, Daniel Nettersheim, Martin Fellermeyer, Simon Schneider, Francois Hafezi, Friedemann Honecker, Valerie Schumacher, Matthias Geyer, Glen Kristiansen and Hubert Schorle: The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo; Journal of Cellular and Molecular Medicine; DOI: 10.1111/jcmm.13059
Daniel Nettersheim, Sina Jostes, Martin Fabry, Friedemann Honecker, Valerie Schumacher, Jutta Kirfel, Glen Kristiansen and Hubert Schorle: A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment; Oncotarget; DOI: 10.18632/oncotarget.11647
Prof. Hubert Schorle
Institute of Pathology
University of Bonn
Telephone: +49 (0)228/28716342
Dr. Andreas Archut | idw - Informationsdienst Wissenschaft
GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University
Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.
Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...
In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
20.04.2018 | Physics and Astronomy
20.04.2018 | Interdisciplinary Research
20.04.2018 | Physics and Astronomy